Skip to content
FATE·Nasdaq·US

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company focused on programmed cellular immunotherapies. It develops iPSC-derived natural killer and T-cell therapies for cancer and autoimmune diseases, and it earns revenue mainly from collaboration and preclinical development agreements.

Recent Activity

Updated Oct 17, 2026
–Fate Therapeutics appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to lead the commercialization of its CAR T-cell therapies.
–Harrell joins as FT819 advances in the RECLAIM-LN Phase 2 trial in lupus nephritis, and brings lupus nephritis and first-in-class launch experience.

Past updates are part of the Pro plan.

Thematic Position

FATE

Relationship Groups

Competitors21

Relationship details are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

regulatory approvalpost-approval enforcement
FDORA grants FDA authority to withdraw accelerated approvals and fine sponsors
SEC 10-QAug 13, 2026

The full regulatory passage is part of the Pro plan.

21 more · Regulatory and geopolitical insights are part of the Pro plan.